Commonwealth Equity Services’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.13M Sell
14,289
-7,624
-35% -$616K ﹤0.01% 2508
2025
Q4
$1.8M Sell
21,913
-3,089
-12% -$239K ﹤0.01% 2077
2025
Q3
$1.75M Sell
25,002
-2,325
-9% -$157K ﹤0.01% 2114
2025
Q2
$1.75M Sell
27,327
-4,914
-15% -$304K ﹤0.01% 2098
2025
Q1
$2.04M Buy
32,241
+6,239
+24% +$420K ﹤0.01% 1897
2024
Q4
$1.73M Buy
26,002
+3,764
+17% +$259K ﹤0.01% 1975
2024
Q3
$1.55M Buy
22,238
+8,433
+61% +$584K ﹤0.01% 2005
2024
Q2
$895K Sell
13,805
-57
-0.4% -$3.61K ﹤0.01% 2371
2024
Q1
$897K Buy
13,862
+256
+2% +$16.7K ﹤0.01% 2335
2023
Q4
$896K Buy
13,606
+1,418
+12% +$82.4K ﹤0.01% 2251
2023
Q3
$695K Sell
12,188
-33
-0.3% -$2.01K ﹤0.01% 2317
2023
Q2
$749K Buy
12,221
+507
+4% +$31.6K ﹤0.01% 2313
2023
Q1
$735 Sell
11,714
-636
-5% -$41K ﹤0.01% 2257
2022
Q4
$784K Buy
12,350
+733
+6% +$46.5K ﹤0.01% 2122
2022
Q3
$684K Buy
11,617
+1,955
+20% +$120K ﹤0.01% 2177
2022
Q2
$557K Sell
9,662
-173
-2% -$9.96K ﹤0.01% 2327
2022
Q1
$610K Buy
9,835
+738
+8% +$45K ﹤0.01% 2359
2021
Q4
$647K Sell
9,097
-421
-4% -$30.5K ﹤0.01% 2312
2021
Q3
$712K Sell
9,518
-413
-4% -$31.5K ﹤0.01% 2199
2021
Q2
$768K Sell
9,931
-431
-4% -$32K ﹤0.01% 2124
2021
Q1
$764K Sell
10,362
-749
-7% -$56.6K ﹤0.01% 2007
2020
Q4
$779K Sell
11,111
-186
-2% -$11.8K ﹤0.01% 1821
2020
Q3
$639K Buy
11,297
+2,445
+28% +$144K ﹤0.01% 1795
2020
Q2
$515K Sell
8,852
-1,566
-15% -$85.3K ﹤0.01% 1859
2020
Q1
$484K Buy
10,418
+101
+1% +$5.27K ﹤0.01% 1717
2019
Q4
$576K Sell
10,317
-6,912
-40% -$360K ﹤0.01% 1800
2019
Q3
$816K Sell
17,229
-505
-3% -$25.9K ﹤0.01% 1488
2019
Q2
$949K Sell
17,734
-270
-1% -$14K ﹤0.01% 1374
2019
Q1
$993K Buy
18,004
+551
+3% +$29.1K ﹤0.01% 1299
2018
Q4
$821K Buy
17,453
+171
+1% +$8.79K ﹤0.01% 1330
2018
Q3
$1.03M Buy
17,282
+167
+1% +$9.74K ﹤0.01% 1283
2018
Q2
$936K Sell
17,115
-340
-2% -$17.3K ﹤0.01% 1314
2018
Q1
$859K Sell
17,455
-437
-2% -$22.3K ﹤0.01% 1341
2017
Q4
$844K Buy
17,892
+231
+1% +$10.8K ﹤0.01% 1335
2017
Q3
$882K Buy
17,661
+14
+0.1% +$664 0.01% 1255
2017
Q2
$806K Sell
17,647
-4,095
-19% -$177K 0.01% 1263
2017
Q1
$919K Sell
21,742
-2,147
-9% -$90K 0.01% 1160
2016
Q4
$927K Sell
23,889
-5,315
-18% -$215K 0.01% 1075
2016
Q3
$1.23M Sell
29,204
-1,725
-6% -$70.8K 0.01% 903
2016
Q2
$1.14M Sell
30,929
-2,335
-7% -$91.6K 0.01% 910
2016
Q1
$1.27M Sell
33,264
-11,402
-26% -$443K 0.01% 844
2015
Q4
$2.26M Buy
44,666
+1,096
+3% +$54.2K 0.02% 583
2015
Q3
$1.99M Buy
43,570
+1,545
+4% +$86.3K 0.02% 598
2015
Q2
$2.45M Sell
42,025
-1,177
-3% -$67.3K 0.02% 552
2015
Q1
$2.38M Buy
43,202
+1,252
+3% +$67.7K 0.02% 547
2014
Q4
$2.11M Buy
41,950
+6,567
+19% +$321K 0.02% 560
2014
Q3
$1.64M Buy
35,383
+1,356
+4% +$61.1K 0.02% 629
2014
Q2
$1.49M Buy
34,027
+5,163
+18% +$209K 0.02% 673
2014
Q1
$1.2M Buy
28,864
+1,289
+5% +$55.2K 0.02% 713
2013
Q4
$1.02M Buy
27,575
+5,048
+22% +$181K 0.01% 757
2013
Q3
$790K Sell
22,527
-3,540
-14% -$117K 0.01% 846
2013
Q2
$753K Buy
+26,067
New +$741K 0.01% 814

Other funds holding PBE

Commonwealth Equity Services's PBE Position: Q1 2026 in Review

Commonwealth Equity Services reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 35% in Q1 2026, selling an estimated $616K and leaving 14,289 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2508.

Commonwealth Equity Services first reported a position in PBE in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.45M in Q2 2015. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

  • Commonwealth Equity Services held 14,289 shares of Invesco Biotechnology & Genome ETF worth $1.13M as of Q1 2026.
  • Commonwealth Equity Services sold 7,624 Invesco Biotechnology & Genome ETF shares in Q1 2026, an estimated $616K.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #2508 holding.
  • Commonwealth Equity Services first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and has held it in 52 quarters since.
  • Commonwealth Equity Services's Invesco Biotechnology & Genome ETF position peaked at $2.45M in Q2 2015.
  • 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.